{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:51:58Z","timestamp":1781711518753,"version":"3.54.5"},"reference-count":9,"publisher":"Norwegian Medical Association","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.23.0338","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T06:00:11Z","timestamp":1701756011000},"source":"Crossref","is-referenced-by-count":2,"title":["Takotsubo syndrome during treatment with 5-fluorouracil"],"prefix":"10.4045","volume":"143","author":[{"given":"Synne Wollen","family":"Steen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halfdan","family":"S\u00f8rbye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Jazbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herish","family":"Garresori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"ref=1","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av kreft i tykktarm og endetarm. https:\/\/www.helsedirektoratet.no\/retningslinjer\/kreft-i-tykktarm-og-endetarm-handlingsprogram Lest 9.10.2023."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Ghadri\u00a0JR, Wittstein\u00a0IS, Prasad\u00a0A et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J 2018; 39: 2032\u201346. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29850871&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Feurheartj%2Fehy076","DOI":"10.1093\/eurheartj\/ehy076"},{"key":"ref=3","unstructured":"Lyon\u00a0AR, L\u00f3pez-Fern\u00e1ndez\u00a0T, Couch\u00a0LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229\u2013361. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36017568&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Feurheartj%2Fehac244"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Sara\u00a0JD, Kaur\u00a0J, Khodadadi\u00a0R et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol 2018; 10: 1758835918780140. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29977352&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F1758835918780140","DOI":"10.1177\/1758835918780140"},{"key":"ref=5","unstructured":"European Medicines Agency (EMA). Fluorouracil Accord (i.v. application). PSUSA-0000007-202012 \u2013 CMDh scientific conclusions and grouns for the variation to the terms of the Marketing Authorisation(s). https:\/\/www.ema.europa.eu\/en\/ Lest 14.3.2023."},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Ghadri\u00a0J-R, Wittstein\u00a0IS, Prasad\u00a0A et al. International expert consensus document on Takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J 2018; 39: 2047\u201362. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29850820&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Feurheartj%2Fehy077","DOI":"10.1093\/eurheartj\/ehy077"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Sattler\u00a0K, El-Battrawy\u00a0I, Lang\u00a0S et al. Prevalence of cancer in Takotsubo cardiomyopathy: Short and long-term outcome. Int J Cardiol 2017; 238: 159\u201365. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28318661&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.ijcard.2017.02.093","DOI":"10.1016\/j.ijcard.2017.02.093"},{"key":"ref=8","unstructured":"Statens legemiddelverk. Preparatomtale (SPC) Teysuno kapsler. https:\/\/www.legemiddelsok.no\/ Lest 9.10.2023."},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Osterlund\u00a0P, Kinos\u00a0S, Pfeiffer\u00a0P et al. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open 2022; 7: 100427. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35798468&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.esmoop.2022.100427","DOI":"10.1016\/j.esmoop.2022.100427"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Takotsubosyndrom under behandling med fluorouracil"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:59:46Z","timestamp":1781708386000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2023\/12\/kort-kasuistikk\/takotsubosyndrom-under-behandling-med-fluorouracil"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":9,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.23.0338","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}